Tirzepatide
$179.99
A first-in-class dual GIP and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing synergistic effects on glucose regulation and energy balance that exceed single-receptor agonists in clinical research.
Certificate of Analysis
Third-party verified · HPLC & Mass Spectrometry
Purity
98.95%
Lot Number
AUR-TIRZ-250118
Test Date
Jan 18, 2025
Laboratory
Janssen Analytik GmbH
Compound Details
Mechanism of Action
Dual agonist with high affinity for the GIP receptor and moderate affinity for the GLP-1 receptor. GIP receptor activation enhances beta-cell insulin secretion and lipid metabolism in adipose tissue, while GLP-1 receptor activation provides appetite suppression and glycemic control. The dual mechanism yields additive metabolic effects.
Molecular Profile
- Molecular Weight
- 4,813.45 Da
- Purity Spec
- ≥98% by HPLC
Storage
Store lyophilized at −20°C. Reconstituted: 2–8°C, use within 21 days. Protect from light.
Research Applications
Published Research
Peer-reviewed studies from PubMed.
First head-to-head Phase 3b trial: tirzepatide produced 20.2% mean weight loss vs 13.7% for semaglutide 2.4 mg at 72 weeks in adults with obesity. Tirzepatide was superior across every weight-loss threshold and demonstrated greater waist circumference reduction.
- 20.2% mean weight loss with tirzepatide vs 13.7% with semaglutide at 72 weeks
- Greater waist circumference reduction (18.4 cm vs 13.0 cm)
- Post-hoc analysis: 2.4% absolute predicted 10-year CVD risk reduction vs 1.4% for semaglutide
Phase 3 SURMOUNT-1 trial: tirzepatide produced weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks in adults with obesity — the largest reductions seen with any anti-obesity medication to date.
- 20.9% mean weight loss at highest dose (15 mg) over 72 weeks
- Over 50% of participants on 15 mg lost ≥20% body weight
- Superior efficacy to any previously approved anti-obesity pharmacotherapy
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)2023Metabolic
Phase 3 SURMOUNT-2 trial: dual GIP/GLP-1 agonist tirzepatide once weekly produced substantial weight reduction in adults with obesity and type 2 diabetes, with improved glycemic control.
- 12.8% (10 mg) and 14.7% (15 mg) weight reduction at 72 weeks
- Significant HbA1c reductions across both dose groups
- Dual mechanism provides simultaneous metabolic and weight benefits
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)2021Metabolic
Head-to-head trial: tirzepatide at all three doses was superior to semaglutide 1 mg for HbA1c reduction and body weight loss in patients with type 2 diabetes.
- All tirzepatide doses superior to semaglutide 1 mg for HbA1c reduction
- Greater weight loss with tirzepatide at every dose level
- First head-to-head evidence of dual agonist superiority over GLP-1 monotherapy
Comprehensive review of the dual-incretin hypothesis: how simultaneous GIP and GLP-1 receptor agonism produces metabolic effects beyond what either hormone achieves alone.
- GIP receptor activation complements GLP-1 effects on beta-cell function
- Dual agonism enhances lipid metabolism in adipose tissue
- Explains the mechanistic basis for tirzepatide’s superior efficacy